Home News & Insights Updates on the APAP and Autism Litigation

Updates on the APAP and Autism Litigation

Reg Reinoso

Author

Midsection of pregnant woman taking medicine at home

Table of Contents

APAP and Autism Litigation Update July 2024

Recent judicial developments have posed significant hurdles in the ongoing litigation regarding acetaminophen (APAP) use during pregnancy. Despite a challenging setback in federal court, Watts Law Firm LLP, alongside our co-counsel, remains committed to pursuing justice for those potentially harmed by prenatal APAP exposure. In December 2023, Judge Cote granted the defense’s Daubert motions, resulting in the exclusion of our general causation experts’ testimonies. This January, a subsequent order under Rule 702 led to the dismissal of all active federal cases due to a lack of admissible general causation evidence. We are currently exploring new scientific evidence that could reinvigorate our case and are considering the possibility of refiling cases for minors in state courts. We are preparing for potential state court litigations and exploring appellate avenues.

Background and Implications of APAP Exposure During Pregnancy

This litigation stems from concerns about the safety of widely recommended acetaminophen during pregnancy. Scientific inquiries have suggested a possible link between APAP exposure and increased risks of neurodevelopmental disorders in children, such as Autism Spectrum Disorder (ASD). Despite acetaminophen’s reputation as a safe pain relief option for pregnant women, recent studies and expert opinions have called this assumption into question, advocating for more cautious use. At Watts Law Firm LLP, we continue to stand with those affected, pushing for accountability and seeking justice through every legal avenue available. We believe in the power of collective action to effect change and uphold the rights of consumers, especially when it concerns the health and future of our children. We will keep you updated on all significant developments regarding this litigation. Your trust in us fuels our continued efforts to seek justice and accountability from pharmaceutical companies. For more detailed information on how we are handling these cases, please contact our office directly. Note that this update is for informational purposes only and is not intended to be legal advice.